WO2024209267 - MODULATORS OF NANOPARTICLE UPTAKE
National phase entry is expected:
Publication Number
WO/2024/209267
Publication Date
10.10.2024
International Application No.
PCT/IB2024/000175
International Filing Date
03.04.2024
Title **
[English]
MODULATORS OF NANOPARTICLE UPTAKE
[French]
MODULATEURS DE L'ABSORPTION DE NANOPARTICULES
Applicants **
JAZZ PHARMACEUTICALS IRELAND LIMITED
Waterloo Exchange, 5th Floor, Waterloo Road
Dublin, D04 E5W7, IE
Inventors
YAMAUCHI, Takahiro
23-3 Matsuoka Shimoaizuki, Eiheiji-cho,
Yoshida-gun
Fukui 910-1193, JP
HOSONO, Naoko
23-3 Matsuoka Shimoaizuki, Eiheiji-cho,
Yoshida-gun
Fukui 910-1193, JP
ARAIE, Hiroaki
23-3 Matsuoka Shimoaizuki, Eiheiji-cho,
Yoshida-gun
Fukui 910-1193, JP
Priority Data
63/493,969
03.04.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1869 | |
| EPO | Filing, Examination | 12069 | |
| Japan | Filing | 531 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 11835 |
Total: 26879 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Various formulations for combination therapy with a liposome and an inhibitor of SR-BI, leading to enhanced uptake of the liposome by a target cell are provided and exemplified by combination therapy with CPX-351 and BLT-1. Also provided are various formulations for combination therapy with a liposome and an ENT inhibitor leading to enhanced uptake of liposome-encapsulated cytarabine by a target cell. Also provided are methods of using the formulations in combination therapy. Also provided is a method of reducing cardiotoxicity in an age-stratified patient population undergoing therapy with cytarabine and daunorubicin, CPX-351.[French]
L'invention concerne diverses formulations pour une polythérapie avec un liposome et un inhibiteur de SRBI, conduisant à une absorption améliorée du liposome par une cellule cible sont fournies et exemplifiées par une polythérapie avec CPX-351 et BLT-1. L'invention concerne également diverses formulations pour une polythérapie avec un liposome et un inhibiteur d'ENT conduisant à une absorption améliorée de cytarabine encapsulée dans des liposomes par une cellule cible. L'invention concerne également des procédés d'utilisation des formulations en polythérapie. L'invention concerne également un procédé de réduction de la cardiotoxicité dans une population de patients stratifiés dans l'âge subissant une thérapie avec de la cytarabine et de la daunorubicine, CPX-351.